Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis.

Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis.

Bibliografiska uppgifter
Huvudupphovsmän: Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Vandenhende, F, Radford, K, Borah, B, Wolfgang, H
Materialtyp: Conference item
Publicerad: 2012

Liknande verk